Trubion Pharmaceuticals Inc. to Present Company Overview and Participate in Panel Discussion at Prestigious Life Science Innovation Northwest 2010

SEATTLE, March 11 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. announced today that it will participate in the upcoming 10th Annual Life Science Innovation Northwest (LSINW) conference to be held at the Bell Harbor International Convention Center, 2211 Alaskan Way, Seattle, on March 16 - 17, 2010. Michelle Burris, senior vice president and chief operating officer, will present a company overview on March 16 at 1:45 p.m. PT, and will also take part in a panel discussion titled, "Investment or Partnership: What is the best deal for your Company?" on March 17 at 3:30 p.m. PT. The goal of the panel discussion is to provide insight on how companies can recognize and capitalize on the best business strategies in today's economy. Both events will take place in the Bay Auditorium.

About Trubion

Trubion is a biopharmaceutical company that is creating a pipeline of novel protein therapeutic product candidates to treat autoimmune and inflammatory diseases and cancer. The Company's mission is to develop a variety of first-in-class and best-in-class product candidates, customized for optimal safety, efficacy and convenience that it believes may offer improved patient experiences. Trubion's current product candidates are novel single-chain protein, or SMIP, therapeutics, and are designed using its custom drug assembly technology. Trubion's product pipeline includes CD20-directed SMIP therapeutics such as TRU-015 and SBI-087 for autoimmune and inflammatory diseases, developed under the Company's Pfizer collaboration. Trubion's product pipeline also includes TRU-016, a novel CD37-targeted therapy for the treatment of B-cell malignancies developed under the company's Facet collaboration. In addition to Trubion's current clinical stage product pipeline, the Company is also developing its multi-specific SCORPION technology, both for targeting cell-surface molecules like CD79b and HLA-DR, as well simultaneously neutralizing soluble ligands like TNF and IL-6. More information is available in the investors section of Trubion's website: http://investors.trubion.com/index.cfm.

Photo: http://www.newscom.com/cgi-bin/prnh/20090320/TRUBIONLOGO
http://photoarchive.ap.org
PRN Photo Desk, photodesk@prnewswire.comTrubion Pharmaceuticals Inc.